Medicare now covers HIV prevention at your pharmacy, not just doctor's office

What it does

This bill expands Medicare Part B coverage to include HIV prevention services (like PrEP and PEP medications, screening, and counseling) when provided by pharmacists, not just physicians. Medicare will pay 80% of the cost (capped at 85% of the physician payment rate), and pharmacists cannot balance-bill patients for these services. The change takes effect January 1, 2027.

Why we flagged it

The bill's core mechanism is straightforward: it adds a new covered service category (pharmacist-provided HIV prevention) to Medicare Part B and sets payment rates. This is routine healthcare coverage policy, not a hidden rider or carve-out.

What the text implies

• Pharmacist scope-of-practice expansion may vary by state law; beneficiaries in states with restrictive pharmacy regulations may see limited practical access despite federal coverage.
• Payment at 85% of physician rates may incentivize pharmacists to provide these services, but actual uptake depends on state licensing, pharmacy chain policies, and pharmacist training availability.
• The bill does not mandate pharmacist training or certification standards for HIV prevention services, relying entirely on state law authorization—quality and consistency may vary.
• Balance-billing prohibition applies only to Medicare; private insurers and state Medicaid programs are not bound by this restriction, creating a two-tier access landscape.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries gain access to HIV prevention services at more convenient locations (pharmacies) with no balance-billing risk, and the payment cap ensures cost control. The expansion of preventive care access to a broader provider network reduces barriers to evidence-based HIV prevention without shifting costs to patients.

Who stands to gain

• Pharmaceutical manufacturers (PrEP/PEP drug volume increase)
• Pharmacy chains and independent pharmacies (new billable service line)
• Clinical laboratory companies (increased HIV screening test volume)

Named in the bill

Medicare Part B, Social Security Act, Pharmacists, PrEP (pre-exposure prophylaxis), PEP (post-exposure prophylaxis), HIV prevention, Centers for Medicare & Medicaid Services (CMS), Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

21 cosponsors: 21 Democrats.

• Jan 21, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jan 21, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.